NASDAQ:CAPR

Capricor Therapeutics Stock Forecast, Price & News

$4.27
+0.01 (+0.23 %)
(As of 08/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.15
$4.40
50-Day Range
$3.79
$5.72
52-Week Range
$3.13
$8.40
Volume130,130 shs
Average Volume659,425 shs
Market Capitalization$97.69 million
P/E RatioN/A
Dividend YieldN/A
Beta6.5
30 days | 90 days | 365 days | Advanced Chart
Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Capricor Therapeutics logo

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

979th out of 1,311 stocks

Pharmaceutical Preparations Industry

485th out of 647 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

Is Capricor Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Capricor Therapeutics?

Wall Street analysts have given Capricor Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Capricor Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Capricor Therapeutics
.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter. The biotechnology company earned $0.04 million during the quarter. Capricor Therapeutics had a negative net margin of 10,074.70% and a negative trailing twelve-month return on equity of 52.82%.
View Capricor Therapeutics' earnings history
.

How has Capricor Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CAPR shares have increased by 324.9% and is now trading at $4.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CAPR?

1 equities research analysts have issued 12-month price targets for Capricor Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Capricor Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 181.0% from the stock's current price.
View analysts' price targets for Capricor Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

Who are some of Capricor Therapeutics' key competitors?

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.49%) and Cutler Group LP (0.00%).
View institutional ownership trends for Capricor Therapeutics
.

Which major investors are buying Capricor Therapeutics stock?

CAPR stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Cutler Group LP.
View insider buying and selling activity for Capricor Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $4.27.

How much money does Capricor Therapeutics make?

Capricor Therapeutics has a market capitalization of $97.69 million and generates $310,000.00 in revenue each year. The biotechnology company earns $-13,660,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

Where are Capricor Therapeutics' headquarters?

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.